CHICAGO, Aug. 17 /PRNewswire-FirstCall/ -- CytoCore, Inc. has announced that the company, formerly listed on the NASDAQ OTCBB market as MCDG.OB, has changed its ticker symbol to CYCR.OB, to finalize the process of changing its name to CytoCore.
CytoCore also announced that the company has launched its new Web site, http://www.cytocoreinc.com . The site’s new look and format offers user-friendly navigation and access to company and product information. Its features include a detailed description of the company’s products and processes, company news updates and presentations, investor information and related health links.
About CytoCore, Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: http://www.cytocoreinc.com .
Certain statements in this release are forward-looking. These statements are based on CytoCore’s current expectations and involve many risks and uncertainties, such as the company’s inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore’s expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore’s current expectation depending upon a number of factors affecting the Company’s business. These factors include, among others, risks and uncertainties detailed in the Company’s periodic public filings with the Securities and Exchange Commission, including but not limited to the Company’s Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
CytoCore, Inc.
CONTACT: Patty Briguglio of MMI Associates, Inc., +1-919-233-6600,patty@mmimarketing.com , or Gene Martineau, Director Communications, ofCytoCore, Inc., +1-212-348-1852, ebm@interport.net
Web site: http://www.cytocoreinc.com/
